Aerpio Pharmaceuticals, Aadi Bioscience to Merge
Aerpio Pharmaceuticals, Aadi Bioscience to Merge
DJ Aerpio Pharmaceuticals, Aadi Bioscience to Merge
DJ Aerpio製藥公司和Aadi生物科學公司將合併
By Michael Dabaie
邁克爾·達拜(Michael Dabaie)著
Aerpio Pharmaceuticals Inc. and privately-held Aadi Bioscience Inc. Monday said they agreed to merge, creating a Nasdaq-listed company focused on advancing Aadi's late-stage pipeline for cancers.
Aerpio製藥公司(Aerpio PharmPharmticals Inc.)和私人持股的Aadi Bioscience Inc.週一表示，他們同意合併，從而創建了一家在納斯達克(Nasdaq)上市的公司，專注於推進Aadi的晚期癌症管道。
Aerpio said it would change its name to Aadi Bioscience Inc. following the merger, with the combined public company focusing on advancing Aadi's lead product candidate Fyarro.
Aerpio表示，合併後將更名為Aadi Bioscience Inc.，合併後的上市公司將專注於推進Aadi的主要候選產品Fya ro。
A rolling new drug application submission to the Food and Drug Administration for Fyarro in advanced malignant perivascular epithelioid sarcoma, or PEComa, is expected to be completed in mid-2021, the company said.
該公司表示，針對Fya ro治療晚期惡性血管周圍上皮樣肉瘤(PEComa)的滾動新藥申請預計將於2021年年中完成。
Aerpio shares rose 6% premarket to $1.23.
Aerpio股價盤前上漲6%，至1.23美元。
Aerpio said it entered into subscription agreements to raise $155 million in a private-investment-in-public-equity financing led by Acuta Capital Partners and KVP Capital. The financing includes Avoro Capital Advisors, Avoro Ventures, Venrock Healthcare Capital Partners, BVF Partners, L.P., Vivo Capital, Alta Bioequities L.P., Rock Springs Capital, RTW Investments LP, Acorn Bioventures and Serrado Capital LLC as well as other undisclosed institutional investors, the company said.
Aerpio説，它達成了認購協議，通過Acuta Capital Partners和KVP Capital牽頭的私募股權投資融資籌集1.55億美元。該公司表示，此次融資包括Avoro Capital Advisors、Avoro Ventures、Venrock Healthcare Capital Partners、BVF Partners，L.P.、Vivo Capital、Alta BioEquities L.P.、Rock Springs Capital、RTW Investments LP、橡子生物風險投資公司和Serrado Capital LLC以及其他未披露的機構投資者。
The company said it expects to use proceeds from the PIPE financing for commercialization of Fyarro in advanced malignant PEComa and a planned trial in solid tumors harboring inactivating alterations in the mTOR pathway genes TSC1 and TSC2. The trial is expected to be initiated by the end of 2021.
該公司表示，預計將利用管道融資所得資金，將Fya ro用於晚期惡性PEComa的商業化，並計劃在mTOR途徑基因TSC1和TSC2存在失活改變的實體腫瘤上進行試驗。該試驗預計將於2021年底啟動。
The combined company is expected to be led by Aadi's Chief Executive Neil Desai and headquartered in Los Angeles.
合併後的公司預計將由Aadi首席執行長尼爾·德賽(Neil Desai)領導，總部設在洛杉磯。
Aadi shareholders will receive shares of newly issued Aerpio common stock. On a pro forma basis, shareholders of Aadi will own about 66.8% and shareholders of Aerpio about 33.2% of the combined company, prior to the additional PIPE financing transaction. Following the closing of the concurrent PIPE financing, Aerpio shareholders will own about 14.7% of the combined company.
AADI股東將獲得新發行的Aerpio普通股。在預計的基礎上，在額外的管道融資交易之前，Aadi的股東將擁有合併後公司約66.8%的股份，Aerpio的股東將擁有約33.2%的股份。在同時進行的管道融資結束後，Aerpio的股東將擁有合併後公司約14.7%的股份。
Write to Michael Dabaie at michael.dabaie@wsj.com
寫信給Michael Dabaie，電子郵件：michael.dabaie@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
May 17, 2021 07:53 ET (11:53 GMT)
2021年5月17日07：53美國東部時間(格林尼治標準時間11：53)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司